Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
Learn how the next generation of regenerative medicine researchers at the University of Toronto and its affiliated hospitals are preparing to translate their discoveries toward impact. Join us on May 19, 2021, from 3 p.m. to 5 p.m. for the Building a Biotech Venture Pitch Competition, when six trainee-led teams will pitch their regenerative medicine-related products or ventures to an expert panel of judges and compete for up to $25,000 in research funding.
The competition is the culmination of Medicine by Design’s Building a Biotech Venture program, offered in partnership with H2i. Over the past three months, the program has offered workshops and mentoring to help teams advance company or product concepts based on their regenerative medicine research. The teams with the highest potential for company creation have been selected to take part in the pitch competition.
To register, please visit https://us02web.zoom.us/webinar/register/WN_j2JsJSssQ-S55e73ydScHw. For more event details, please visit https://mbd.utoronto.ca/event/pitch-competition-building-a-biotech-venture-program/.